Breaking News

Galena, Teva in Commercialization Pact

December 4, 2012

To market breast cancer drug NeuVax in Israel

Galena Biopharma has signed an agreement with a subsidiary of Teva Pharmaceutical Industries for the commercialization of the breast cancer drug NeuVax in Israel. Teva Israel will assume responsibility for regulatory registration, provide financial support for development, and will commercialize the product in the region. Galena is eligible to receive royalty payments on future sales.
 
"This agreement is the first piece of our global commercialization strategy," said Mark Ahn, Ph.D., president and chief executive officer, Galena Biopharma. "Teva is a world-class pharmaceutical company and a major pharmaceutical company in Israel. We look forward to their valuable financial support towards our development goals in Israel, as well as market leadership for NeuVax commercialization in the region."

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016